File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival

TitleHigh expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival
Authors
KeywordsBreast cancer
Estrogen receptor
MALAT1
Meta-analysis
Survival
Issue Date2018
Citation
Breast Cancer Research and Treatment, 2018, v. 171, n. 2, p. 261-271 How to Cite?
AbstractPurpose: Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has been identified as a prognostic marker for the metastasis of early-stage non-small cell lung cancer (NSCLCs). We studied MALAT1 expression in breast cancer in relation to disease features and patient survival. Methods: Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was used to measure MALAT1 expression in tumor samples of 509 breast cancer patients. Hazards ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the association between MALAT1 expression and breast cancer survival using the Cox proportional hazards regression model, and the analysis was adjusted for age at surgery, tumor grade, disease stage, and hormone receptor status. Meta-analysis of multiple microarray datasets from online databases and our own study was performed to evaluate the association of MALAT1 with breast cancer survival. Results: Patients with low-grade or ER-positive tumors had higher expression of MALAT1 compared to those with high-grade (p = 0.013) or ER-negative (p = 0.0002) tumors. Patients with PR-positive tumors also had higher MALAT1 expression than those with PR-negative tumors (p < 0.0001). In patients with positive hormone receptors or low tumor grade, tumors with high MALAT1 expression were more likely to recur. Survival analysis showed that patients with high expression of MALAT1 had a twofold increase in risk of relapse (p = 0.0083) compared to those with low expression. This association remained significant after adjustment for age at surgery, disease stage, tumor grade, and hormone receptor status. Meta-analysis showed that high MALAT1 expression was associated with poor relapse-free survival in patients with hormone receptor-positive tumors (HR 1.44, 95% CI 1.08–1.92). Conclusions: High expression of lncRNA MALAT1 is associated with breast cancer relapse and may play a role in tumor progression.
Persistent Identifierhttp://hdl.handle.net/10722/342566
ISSN
2023 Impact Factor: 3.0
2023 SCImago Journal Rankings: 1.267
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWang, Zhanwei-
dc.contributor.authorKatsaros, Dionyssios-
dc.contributor.authorBiglia, Nicoletta-
dc.contributor.authorShen, Yi-
dc.contributor.authorFu, Yuanyuan-
dc.contributor.authorLoo, Lenora W.M.-
dc.contributor.authorJia, Wei-
dc.contributor.authorObata, Yuki-
dc.contributor.authorYu, Herbert-
dc.date.accessioned2024-04-17T07:04:42Z-
dc.date.available2024-04-17T07:04:42Z-
dc.date.issued2018-
dc.identifier.citationBreast Cancer Research and Treatment, 2018, v. 171, n. 2, p. 261-271-
dc.identifier.issn0167-6806-
dc.identifier.urihttp://hdl.handle.net/10722/342566-
dc.description.abstractPurpose: Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has been identified as a prognostic marker for the metastasis of early-stage non-small cell lung cancer (NSCLCs). We studied MALAT1 expression in breast cancer in relation to disease features and patient survival. Methods: Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was used to measure MALAT1 expression in tumor samples of 509 breast cancer patients. Hazards ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the association between MALAT1 expression and breast cancer survival using the Cox proportional hazards regression model, and the analysis was adjusted for age at surgery, tumor grade, disease stage, and hormone receptor status. Meta-analysis of multiple microarray datasets from online databases and our own study was performed to evaluate the association of MALAT1 with breast cancer survival. Results: Patients with low-grade or ER-positive tumors had higher expression of MALAT1 compared to those with high-grade (p = 0.013) or ER-negative (p = 0.0002) tumors. Patients with PR-positive tumors also had higher MALAT1 expression than those with PR-negative tumors (p < 0.0001). In patients with positive hormone receptors or low tumor grade, tumors with high MALAT1 expression were more likely to recur. Survival analysis showed that patients with high expression of MALAT1 had a twofold increase in risk of relapse (p = 0.0083) compared to those with low expression. This association remained significant after adjustment for age at surgery, disease stage, tumor grade, and hormone receptor status. Meta-analysis showed that high MALAT1 expression was associated with poor relapse-free survival in patients with hormone receptor-positive tumors (HR 1.44, 95% CI 1.08–1.92). Conclusions: High expression of lncRNA MALAT1 is associated with breast cancer relapse and may play a role in tumor progression.-
dc.languageeng-
dc.relation.ispartofBreast Cancer Research and Treatment-
dc.subjectBreast cancer-
dc.subjectEstrogen receptor-
dc.subjectMALAT1-
dc.subjectMeta-analysis-
dc.subjectSurvival-
dc.titleHigh expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s10549-018-4839-2-
dc.identifier.pmid29845475-
dc.identifier.scopuseid_2-s2.0-85047663164-
dc.identifier.volume171-
dc.identifier.issue2-
dc.identifier.spage261-
dc.identifier.epage271-
dc.identifier.eissn1573-7217-
dc.identifier.isiWOS:000440766500002-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats